Doctors call for public patients to have access to breakthrough therapy for prostate cancer

The doctors wrote to HSE CEO Bernard Gloster (pictured) this week asking for negotiations with the makers of Pluvicto to continue. Photo: Moya Nolan

A new therapy “likely to change the face of prostate cancer treatment” for men should be funded for public patients, according to almost 40 cancer consultants.

The doctors wrote to HSE CEO Bernard Gloster this week asking for negotiations with the makers of Pluvicto to continue. It benefits men with advanced metastatic prostate cancer. It was approved in France earlier this week and is used across eight EU countries and elsewhere.